In a headline-grabbing move that’s shaking up the dental device sector, ArchiMed, a France-based healthcare investment powerhouse, has announced plans to acquire ZimVie Inc. for a jaw-dropping $730 million. The all-cash deal, unveiled Monday, will see ArchiMed scoop up all outstanding shares of the Florida-headquartered dental implant company at $19 per share—a staggering 99% premium over ZimVie's 90-day average trading price.

The market didn’t take long to react. ZimVie’s stock surged 122%, rocketing to $18.74 per share in Monday afternoon trading, proving that investors are already biting into ArchiMed’s bold vision.

Latham & Watkins and Cravath Steer Legal Strategy

Latham & Watkins LLP is advising ArchiMed on the blockbuster deal, while Cravath Swaine & Moore LLP, ZimVie's longtime legal partner, is guiding the dental company. The Cravath team is led by seasoned partners Robert I. Townsend III and Matthew G. Jones.

The deal includes a 40-day “go-shop” clause, allowing ZimVie to solicit competing offers until August 29, with Centerview Partners serving as financial advisor during the process.

ZimVie Turns a New Page

For ZimVie, this acquisition isn’t just a transaction—it’s a transformation. CEO Vafa Jamali called it a “new chapter,” noting that ArchiMed’s financial strength and strategic vision will enable ZimVie to broaden its global footprint and scale its innovative dental technologies.

“This partnership provides the strategic and financial backing to expand our dental technology to more patients globally,” Jamali said.

ZimVie, a 2022 spin-off of Zimmer Biomet, has focused aggressively on dental implants after divesting its spine and bone-healing division last year in a $375 million sale to H.I.G. Capital. That strategic pivot, Jamali said at the time, was designed to let ZimVie "double down" on its most promising market.

ArchiMed’s Play for Market Dominance

ArchiMed is known for going deep, not wide. The private equity firm, with €8 billion ($9.4 billion) in assets under management and offices across Europe, North America, and Asia, is laser-focused on healthcare. This acquisition will grant it an immediate and powerful foothold in the high-margin, fast-growing dental technology space.

“ZimVie has strong fundamentals and compelling growth potential,” said André-Michel Ballester, managing partner at ArchiMed. “We’re excited to support its next chapter.”

Once the deal closes—anticipated by late 2025, pending regulatory and shareholder approvals—ZimVie will go private and delist from Nasdaq, enabling it to operate under ArchiMed’s umbrella with fewer public pressures and more room to innovate.

What’s Next?

With both boards unanimously approving the deal, all eyes now turn to potential competing bids during the go-shop window. But whether another suitor steps forward or not, one thing is clear: ArchiMed is betting big on the future of dental health—and it’s a bet Wall Street is watching closely.